株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

急性呼吸促迫症候群(ARDS):パイプライン分析

Acute Respiratory Distress Syndrome - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 192441
出版日 ページ情報 英文 97 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
急性呼吸促迫症候群(ARDS):パイプライン分析 Acute Respiratory Distress Syndrome - Pipeline Review, H2 2016
出版日: 2016年07月30日 ページ情報: 英文 97 Pages
概要

急性呼吸促迫症候群(ARDS)は、肺の中の小さな弾性の空気嚢(肺胞)に体液が溜まると生じます。よく見られる根本的な原因として、敗血症、有害物質の吸入、重症肺炎、頭部や胸部の外傷などが挙げられます。兆候と症状は、重度の息切れ、呼吸困難、異常に速い呼吸、低血圧、精神錯乱、極度の疲労などが見られます。

当レポートでは、急性呼吸促迫症候群(ARDS)に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

急性呼吸促迫症候群(ARDS)の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • Altor BioScience Corporation
  • Athersys, Inc.
  • Faron Pharmaceuticals Oy
  • FirstString Research, Inc.
  • GlaxoSmithKline Plc
  • Histocell S.L.
  • Phylogica Limited
  • Serendex Pharmaceuticals A/S
  • Silence Therapeutics Plc
  • Therabron Therapeutics, Inc.

治療薬の評価

  • 単独療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • ALT-836
  • BIO-10901
  • CG-367
  • Cyndacel-M
  • GSK-2586881
  • GSK-2862277
  • インターフェロンβ-1a
  • molgramostim
  • 感染症・呼吸器疾患用 uPA阻害モノクローナル抗体
  • 肺動脈高血圧症用エンドセリン-1阻害オリゴヌクレオチド
  • PF-05285401
  • PYC-35
  • PYC-36
  • PYC-38
  • PYC-98
  • 急性肺損傷・急性呼吸促迫症候群用組換タンパク質
  • S-1229
  • SAN-101
  • 免疫学・呼吸器/筋骨格障害用MMP・サイトカイン阻害小分子
  • 炎症性肺疾患用幹細胞療法
  • 急性呼吸促迫症候群用間質細胞療法
  • 急性肺損傷・急性呼吸促迫症候群用合成ペプチド

パイプライン製品の最新動向

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8319IDB

Summary

Global Markets Direct's, 'Acute Respiratory Distress Syndrome - Pipeline Review, H2 2016', provides an overview of the Acute Respiratory Distress Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Respiratory Distress Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Respiratory Distress Syndrome and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Acute Respiratory Distress Syndrome
  • The report reviews pipeline therapeutics for Acute Respiratory Distress Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Acute Respiratory Distress Syndrome therapeutics and enlists all their major and minor projects
  • The report assesses Acute Respiratory Distress Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Acute Respiratory Distress Syndrome

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Acute Respiratory Distress Syndrome
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Acute Respiratory Distress Syndrome pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Acute Respiratory Distress Syndrome Overview
  • Therapeutics Development
    • Pipeline Products for Acute Respiratory Distress Syndrome - Overview
    • Pipeline Products for Acute Respiratory Distress Syndrome - Comparative Analysis
    • Acute Respiratory Distress Syndrome - Therapeutics under Development by Companies
    • Acute Respiratory Distress Syndrome - Therapeutics under Investigation by Universities/Institutes
  • Acute Respiratory Distress Syndrome - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Acute Respiratory Distress Syndrome - Products under Development by Companies
  • Acute Respiratory Distress Syndrome - Products under Investigation by Universities/Institutes
  • Acute Respiratory Distress Syndrome - Companies Involved in Therapeutics Development
    • Altor BioScience Corporation
    • Athersys, Inc.
    • Faron Pharmaceuticals Oy
    • FirstString Research, Inc.
    • GlaxoSmithKline Plc
    • Global Blood Therapeutics, Inc.
    • Hydra Biosciences, Inc.
    • Phylogica Limited
    • S-Evans Biosciences, Inc.
    • Savara Inc.
    • Silence Therapeutics Plc
  • Acute Respiratory Distress Syndrome - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ALT-836 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BIO-10901 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BIO-11006 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GBT-440 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2586881 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2862277 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HC-067047 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • interferon beta-1a - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LT-0011 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • molgramostim - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit uPA for Infectious Disease and Respiratory Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Oligonucleotide to Inhibit Endothelin-1 for CVS, Oncology and Respiratory Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-05285401 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PYC-35 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PYC-36 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PYC-38 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PYC-98 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Proteins for Acute Lung Injury and Acute Respiratory Distress Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-1229 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAN-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit MMP and Cytokine for Immunology, Respiratory and Musculoskeletal Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Acute Respiratory Distress Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Metabolic, Gastrointestinal, Multiple Organ Failure and Respiratory Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide for Acute Lung Injury and Acute Respiratory Distress Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Acute Respiratory Distress Syndrome - Dormant Projects
  • Acute Respiratory Distress Syndrome - Discontinued Products
  • Acute Respiratory Distress Syndrome - Product Development Milestones
    • Featured News & Press Releases
      • May 25, 2016: First patient dosed in Savaras pivotal trial for PAP
      • Mar 01, 2016: Faron files patent application to further strengthen protection for its novel Traumakine (FP-1201-lyo) formulation
      • Jan 07, 2016: Positive top-line results from the Japanese Phase II study of Traumakine for the treatment of ARDS
      • Dec 29, 2015: First Patient recruited in Pan-European Phase III INTEREST study for treatment of acute respiratory distress syndrome
      • Oct 19, 2015: Serendex to initiate pivotal phase II/III clinical trial for PAP
      • Aug 09, 2015: Serendex to initiate first phase II clinical trial
      • Jun 10, 2015: Recruitment of ARDS patients for Serendex phase II clinical trial to commence in November
      • May 27, 2015: Phase I clinical trial of inhaled molgramostim has commenced
      • May 20, 2015: Novozymes Biopharma enables stable formulation of Serendex Pharmaceutical's inhalable biological drug for treatment of severe pulmonary diseases
      • May 10, 2015: Positive topline data from Serendex phase I clinical trial
      • Feb 27, 2015: Serendex submits phase I application
      • Feb 13, 2015: Serendex partners up with leading German lung center
      • Jan 28, 2015: Serendex receives positive scientific advice from EMA
      • Jan 22, 2015: Athersys and Cell Therapy Catapult Announce Grant to Support Clinical Development of Stem Cell Therapy for Severe Acute Respiratory Condition
      • Dec 10, 2014: Serendex Registers First Sale Of Molgradex
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Acute Respiratory Distress Syndrome, H2 2016
  • Number of Products under Development for Acute Respiratory Distress Syndrome - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Acute Respiratory Distress Syndrome - Pipeline by Altor BioScience Corporation, H2 2016
  • Acute Respiratory Distress Syndrome - Pipeline by Athersys, Inc., H2 2016
  • Acute Respiratory Distress Syndrome - Pipeline by Faron Pharmaceuticals Oy, H2 2016
  • Acute Respiratory Distress Syndrome - Pipeline by FirstString Research, Inc., H2 2016
  • Acute Respiratory Distress Syndrome - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Acute Respiratory Distress Syndrome - Pipeline by Global Blood Therapeutics, Inc., H2 2016
  • Acute Respiratory Distress Syndrome - Pipeline by Hydra Biosciences, Inc., H2 2016
  • Acute Respiratory Distress Syndrome - Pipeline by Phylogica Limited, H2 2016
  • Acute Respiratory Distress Syndrome - Pipeline by S-Evans Biosciences, Inc., H2 2016
  • Acute Respiratory Distress Syndrome - Pipeline by Savara Inc., H2 2016
  • Acute Respiratory Distress Syndrome - Pipeline by Silence Therapeutics Plc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Acute Respiratory Distress Syndrome - Dormant Projects, H2 2016
  • Acute Respiratory Distress Syndrome - Dormant Projects (Contd..1), H2 2016
  • Acute Respiratory Distress Syndrome - Dormant Projects (Contd..2), H2 2016
  • Acute Respiratory Distress Syndrome - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Acute Respiratory Distress Syndrome, H2 2016
  • Number of Products under Development for Acute Respiratory Distress Syndrome - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top